Clinical trial
Randomised, Double-blind, Placebo-controlled, Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy
NCT02368587 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised, Double-blind, Placebo-controlled, Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy
- Lead sponsor
- Navy General Hospital, Beijing
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 1, 2020
- Completion date
- July 31, 2021
- Enrollment
- 160 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
ischemic cardiomyopathy